We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Immunosuppression for Autoimmune Retinopathy

Lee M. Jampol, MD; Gerald A. Fishman, MD
Arch Ophthalmol. 2009;127(4):573-575. doi:10.1001/archophthalmol.2009.51.
Text Size: A A A
Published online


In this month's issue of Archives, Ferreyra and coworkers1 report their experience treating patients who have autoimmune retinopathy (AIR) with immunosuppression. Included among the 30 patients in their retrospective study were 6 patients with cancer-associated retinopathy, 13 with nonparaneoplastic AIR, and 11 with nonparaneoplastic AIR with cystoid macular edema.

Outcome measures that the authors used included an improvement in Snellen visual acuity by 2 or more lines, expansion of the visual field by more than 25%, resolution of cystoid macular edema, and improvement in electroretinogram (ERG) amplitudes. The authors cited an improvement in 21 of their 30 patients (70%): 100% of patients with cancer-associated retinopathy, 54% of patients with nonparaneoplastic AIR, and 73% of patients with nonparaneoplastic AIR with cystoid macular edema. Five of the 21 patients (24%) showed improvement in visual acuity; 15 of 21 (71%) improved their visual field area; while 6 of 11 (53%) showed a resolution of cystoid macular edema. The authors conclude that in this cohort of patients, immunosuppression resulted in clinical improvement for all subgroups of patients, especially those with cancer-associated retinopathy.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

9 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles